Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298,357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.
Huang J, Wang Y, Zhang H, Hu X, Wang P, Cai W, Yuan Y, Zeng H, Zhang J, Kong W, Huang Y, Wang S, Guo J, Wei Q, Xue W. Huang J, et al. Among authors: wang y, wang p, wang s. Cancer Commun (Lond). 2021 Oct;41(10):1071-1074. doi: 10.1002/cac2.12206. Epub 2021 Aug 7. Cancer Commun (Lond). 2021. PMID: 34363742 Free PMC article. No abstract available.
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.
Huang J, Wang Y, Xu F, Wang Z, Wu G, Kong W, Cheoklong NG, Tricard T, Wu X, Zhai W, Zhang W, Zhang J, Zhang D, Chen S, Lian Y, Chen Y, Zhang J, Huang Y, Xue W. Huang J, et al. Among authors: wang z, wang y. J Immunother Cancer. 2024 Jun 11;12(6):e008475. doi: 10.1136/jitc-2023-008475. J Immunother Cancer. 2024. PMID: 38862251 Free PMC article. Clinical Trial.
298,357 results
You have reached the last available page of results. Please see the User Guide for more information.